Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value
$3.88+0.06 (+1.57%)
Close on Nov 11, 2026Market cap $767.65MP/E 3.5Yield –
Arbutus Biopharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$10.48M | -799.4% |
| Q2 FY2026 | Jun 30, 2026 | -$5.95M | – |
| Q1 FY2026 | Mar 31, 2026 | $168.92M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.65M | – |
| Q2 FY2025 | Jun 30, 2025 | $1.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.37M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.10M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.01M | – |
| Q3 FY2023 | Sep 30, 2023 | -$21.19M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.04M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.08M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.47M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.73M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.96M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.21M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.23M | – |
| Q3 FY2020 | Sep 30, 2020 | -$14.73M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.64M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.65M | – |
| Q3 FY2019 | Sep 30, 2019 | -$90.52M | – |
| Q2 FY2019 | Jun 30, 2019 | -$20.14M | – |
| Q1 FY2019 | Mar 31, 2019 | -$18.69M | – |
| Q3 FY2018 | Sep 30, 2018 | -$31.93M | – |
| Q2 FY2018 | Jun 30, 2018 | -$21.47M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.80M | – |
See a number that looks wrong?